Revolution Medicines, Inc.
RVMD
Jodie situation report
Revolution Medicines, Inc.'s move is being confirmed by its market group.
RVMD accounts for 9.4% of the group's measured movement across 3.9 effective names. raw member direction is mixed; 3 of 5 session-normalized paths align to the downside. Capital-flow agreement is 29%, so confirmation is not yet clean. No verified headline preceded the measured group move.
Is this move genuinely shared?
IDYA, CELC moved materially before RVMD. RVMD crossed its material path threshold at 10:40 ET, 70 minutes after the first measured mover. BCRX, ABVX followed.
5 of 5 members in Clinical Biotechnology are active. 0 of 8 disclosed connections are confirming.
- At least 4 of 5 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as ABCL begins moving with the group.
Invalidation: The live read weakens if participation falls to 1 of 5 members or fewer.
Who this business touches
The relationships behind RVMD
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
TNGXTango Therapeutics, Inc.partnerMay 6, 2026 ▾
“Tango Collaboration 80 In November 2024, we entered into a clinical collaboration with Tango Therapeutics, Inc.”
SNYSanofipartnerFeb 25, 2026 ▾
“Sanofi collaboration agreement In June 2018, the Company entered into a collaborative research, development and commercialization agreement (the Sanofi Agreement) with Aventis, Inc.”
Depended on by
TNGXTango Therapeutics, Inc.partnerMay 13, 2026 ▾
“Clinical Trial Collaboration and Supply Agreements In November 2024, the Company and Revolution Medicines, Inc.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 17 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
RVMD is currently a Early Follower in the organic co-movement group Clinical Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.